Breaking Finance News

Intercept Pharma (NASDAQ:ICPT) stock price target increased to $244.00, issued a research note today by RBC Capital

In a report released on 09/15/2017 RBC Capital increased the stock price target of Intercept Pharma (NASDAQ:ICPT) to $244.00 indicating a possible upside of 1.79%.

Yesterday Intercept Pharma (NASDAQ:ICPT) traded 6.62% higher at $87.56. The company’s 50-day moving average is $109.46 and its 200-day moving average is $116.57. The last closing price is down -20.05% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. 1,138,832 shares of the stock traded hands, up from an average trading volume of 572,128

See Chart Below

Intercept Pharma (NASDAQ:ICPT)

Intercept Pharma has a 52 week low of $85.88 and a 52 week high of $172.95 The company’s market cap is currently $0.

In addition to RBC Capital reporting its stock price target, a total of 17 brokers have issued a research note on the company. The average stock price target is $222.82 with 5 brokers rating the stock a strong buy, 8 brokers rating the stock a buy, 3 brokers rating the stock a hold, 2 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Intercept Pharma (NASDAQ:ICPT)

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.